BRISTOL MYERS SQUIBB CO

For the period ended Mar 31, 2025. Filed Apr 24, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed Apr 24, 2025

BMY$62.140.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Summary of Abbreviated Terms

Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:

2024 Form 10-K	Annual Report on Form 10-K for the fiscal year ended December 31, 2024	MDS	myelodysplastic syndromes
2024 Senior Unsecured Notes	Aggregate principal amount of $13.0 billion of senior unsecured notes issued by BMS in February 2024	Merck	Merck & Co.
2seventy bio	2seventy bio, Inc.	Mirati	Mirati Therapeutics, Inc.
aGVHD	acute graft-versus-host disease	MPM	malignant pleural mesothelioma
ADC	antibody-drug conjugate	MTA	Methylthioadenosine
ADP	adenosine diphosphate	MZL	marginal zone lymphoma
ANDA	Abbreviated New Drug Application	NDA	New Drug Application
AOCI	Accumulated other comprehensive loss	nHCM	Nonobstructive Hypertrophic Cardiomyopathy
BCMA	B-cell maturation antigen-directed	NHL	Non-Hodgkin's Lymphoma
BioArctic	BioArctic AB	NKT	natural killer T
CAR-T	chimeric antigen receptor T-cell	NSCLC	non-small cell lung cancer
Celgene	Celgene Corporation	NTRK	Neurotrophic Tropomyosin Receptor Kinase
CERCLA	U.S. Comprehensive Environmental Response, Compensation and Liability Act	Nimbus	Nimbus Therapeutics
CGDP	Coverage Gap Discount Program	NVAF	non-valvular atrial fibrillation
CHMP	Committee for Medicinal Products for Human Use	OECD	Organization for Economic Co-operation and Development
CLL	Chronic Lymphocytic Leukemia	oHCM	Obstructive Hypertrophic Cardiomyopathy
CML	chronic myeloid leukemia	Ono	Ono Pharmaceutical Co., Ltd
CRC	colorectal carcinoma	PD-1	programmed cell death protein 1
CTLA4	Cytotoxic T-lymphocyte Antigen-4	PD-LI	programmed death-ligand 1
CVR	Contingent value right	PDUFA	Prescription Drug User Fee Act
DLBCL	Diffuse Large B-cell Lymphoma	PE	pulmonary embolism
DVT	deep vein thrombosis	PRMT5	protein arginine methyltransferase 5
EC	European Commission	PsA	psoriatic arthritis
EMA	European Medicines Agency	Quarterly Report on Form 10-Q	Quarterly Report on Form 10-Q for the quarter ended March 31, 2025
EPS	earnings per share	R&D	research and development
EU	European Union	RA	rheumatoid arthritis
Exchange Act	the Securities Exchange Act of 1934	RayzeBio	RayzeBio, Inc.
FASB	Financial Accounting Standards Board	RCC	renal cell carcinoma
FDA	U.S. Food and Drug Administration	RDFV	readily determinable fair values
FL	follicular lymphoma	REMS	risk evaluation and mitigation strategy
GAAP	generally accepted accounting principles	Roche	F. Hoffman-La Roche & Co.
GTN	gross-to-net	RPT	radiopharmaceutical therapeutics
HCC	hepatocellular carcinoma	RS	ring sideroblast
HCM	hypertrophic cardiomyopathy	Sanofi	Sanofi S.A.
HHS	Health and Human Services	SEC	U.S. Securities and Exchange Commission
IPRD	in-process research and development	SLL	Small Lymphocytic Lymphoma
IRA	Inflation Reduction Act of 2022	SPC	Supplementary Protection Certificate
IRS	Internal Revenue Service	SystImmune	SystImmune, Inc.
JIA	juvenile idiopathic arthritis	TCJA	Tax Cuts and Jobs Act
Karuna	Karuna Therapeutics, Inc.	UC	ulcerative colitis
KRAS	Kirsten rat sarcoma	UK	United Kingdom
LBCL	Large B-cell Lymphoma	U.S.	United States
MCL	mantle cell lymphoma	VAT	value added tax

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.